Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2024-01-29
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the ATH-063 drug (single and multiple doses) in
Healthy Subjects. The clinical trial aims to evaluate the below.
1. Safety of the drug
2. Tolerability of the drug
3. Pharmacokinetics (PK) (how the human body affects the drug)
4. Pharmacodynamics (PD) (how the drug affects the human body)
This will be a single center, Phase 1, First-In-Human, Randomized, Double-Blind (neither the
subjects nor the experimenters know which subjects are in the test and control groups),
Placebo (a look-alike substance that contains no active drug) - Controlled Study.
Phase:
Phase 1
Details
Lead Sponsor:
Athos Therapeutics Inc
Collaborators:
Athos Therapeutics Australia Pty Ltd Syneos Health